Mechanism, evidence, and regulatory status for 30 of the most-discussed peptides in circulation. We publish what the research actually shows — including, often, that it shows very little.
Most peptide information online flattens everything into one confident voice — an FDA-approved drug with 20,000 trial participants reads the same as a tetrapeptide with no receptor and no replication. We grade each entry so the distinction is visible before you read a word of the biology.
Organised by what these molecules actually do at the receptor, not by the outcome someone hopes to sell.
Incretin and amylin pathways — the most clinically validated class here.
9 PEPTIDESGHRH analogs and ghrelin-receptor secretagogues acting on pituitary GH release.
4 PEPTIDESCytoprotection and tissue healing. Heavy preclinical literature, thin human evidence.
1 PEPTIDEThymic peptides modulating T-cell maturation and innate signalling.
4 PEPTIDESMitochondrial-derived peptides and membrane-targeting agents.
3 PEPTIDESPeptides acting on CNS signalling, cognition, and anxiety.
2 PEPTIDESMelanocortin receptor agonists — the widest safety spread in the library.
1 PEPTIDEUpstream regulators of the hypothalamic-pituitary-gonadal axis.
Regulatory status moved twice in three years and is before an FDA advisory committee now.
Tier 3 · Limited Human DataOne of the few peptides here with a definitive human answer — it failed Phase 2b.
Tier 5 · Minimal DataMultiple national health agencies have issued public warnings against it.
Tier 1 · FDA ApprovedThe benchmark: what a fully evidenced peptide actually looks like.
We do not publish dosing, reconstitution, administration, or cycling protocols. Not for any peptide on this site, including the FDA-approved ones. This is a deliberate editorial line, and it is worth explaining plainly rather than burying in a disclaimer.
For unapproved substances, no honest dosing guidance exists to give. A protocol implies a known therapeutic window — a dose demonstrated to produce a benefit at an acceptable risk in humans. For most peptides in this library, that work has never been done. Publishing numbers anyway would manufacture a false impression of established practice out of forum consensus and vendor copy.
For the approved ones, dosing is a physician's job, individualised to a patient, with monitoring. A web page is not a substitute for that, and pretending otherwise helps nobody.
Receptor-level mechanism, an honest account of what has and has not been demonstrated in humans, current regulatory status including where it is actively changing, and the documented safety signals — cited, and graded.